老年女性乳腺癌患者新辅助内分泌治疗效果的临床研究

许莹

（山东省博兴县人民医院，山东 滨州，256500）

浏览次数：137次 下载次数：263次

摘要：

目的 明确新辅助内分泌治疗在老年女性乳腺癌患者中的临床效果及安全性，比较三种AI内分泌药物（阿那曲唑，来曲唑及依西美坦）的疗效及不良反应情况。方法回顾性分析2010年8月至2013年2月我院收治的72例乳腺癌患者的临床 资料。将选择国产阿那曲唑者21例设为A组，选择国产来曲唑者33例设为B组，选择依西美坦者18例，设为C组。三组患者口服用药12～15个月，记录三组患者客观缓解率（ORR）、临床收益率（CB）、疾病部分缓解率（PR）、临床稳定率（SD）值及药物不良反应发生率。结果 采用内分泌药物治疗后，患者ORR 为45.8%，CB为77.8%。A 组PR为42.9%，SD为47.6%；B 组PR 为36.4%，SD为24.2%；C组PR 为66.7%，SD为27.8%。试验组中应用的三种芳香化酶抑制剂药物不良反应中恶心、面部潮红、潮热的发生率较高。结论 新辅助内分泌治疗可以明显缓解老年患者局部症状，这为不能进行手术和不愿接受化疗、放疗的老年患者提供了一种治疗方式，同时升高了老年患者生存的期望值，也增强了患者继续治疗的信心。

关键词：新辅助内分泌治疗；阿那曲唑；来曲唑；依西美坦

中图分类号：R737.9 文献标志码：A文章编号：2096-1413(2016)25-0009-03

The clinical study of neoadjuvant endocrine therapy on the elder female breast cancer patients
XU Ying
(the People`s Hospital of Boxing County, Binzhou 256500, China)

ABSTRACT: Objective To assess the efficacy and safety of neoadjuvant endocrine therapy (NET) for elder female breast cancer patients, and compare the efficaly and adverse reactions among the three endocrine medicines (anastrozole, letrozole, exemestane) after treatment. Methods Seventy-two cases of elder female breast cancer patients` clinical data in our hospital from August 2010 to February 2013 were retrospectively analyzed. And 21 cases who accepted anastrozole were classified to group A, 33 cases who accepted letrozoleas were classified to group B, 18 cases who accepted exemestane were classified to group C. The patients in the three groups all took the medicine orally and lasted for 12 to 15 months, then the levels of ORR, CB, PR, SD and incidence rate of adverse reactions were compared among the three groups. Results After accepted NET, the ORR was 45.8%, the CB was 77.8%. In group A, the  PR was 42.9%, the SD was 47.6%; in group B, the  PR was 36.4%, the SD was 24.2%; in group C, the  PR was 66.7%, the SD was 27.8%. On aspects of drug complications, the three aromatase inhibitors showed high rate of nausea, flush and hot flash. Conclusion For elder female breast cancer patients, NET has a remarkable efficacy on alleviating local symptoms, which provides a new therapy for patients who can`t accepted surgery, chemotheropy or radiotherapy, and it rises patients` expection of living and confidence for the treatment.
KEYWORDS: neoadjuvant endocrine therapy; anastrozole; letrozole; exemestane

参考文献：
[1] BEATSON GT.Classics in oncology:on the treatment of inoperable cases of carcinoma of the mamma:suggestions for a new method of treatment with illustrative cases[J].CA:A cancer Journal for Clinicians,1983,33 (22):108-121.
[2] VALENZUELA M,JULIAN TB.Neo -adjuvanthormonal therapy [J]. Breast,2008,14(3):279-283.
[3] MATHEW J,ASGEIRSSON KS,JACKSON LR,et al.Neoadjuvant endocrine treatment inprimary breast cancer-review of literature[J].Breast,2009,18(6):339-344.
[4] 夏想厚,谷俊朝.乳腺癌新辅助内分泌治疗的研究进展[J].中华肿瘤防治杂志,2010,12(17):2066-2068.
[5] GUNDUZ N,FISHER B,SAFFER EA.Effect of surgical removal on the growth and kinetics of residual tumor[J].Cancer Res,1979,39(10): 3861-3865.
[6] CHIA YH,ELLIS MJ,MA CX.Neoadjuvantendocrine therapy in primary breast can-cer: indications and use as a research tool[J].Br J Cancer,2010,103(6):759-764.
[7] ELLIS MJ,SUMAN VJ,HOOG J,et al.Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women withestrogen receptor-rich stage 2 to 3 breastcancer: clinical and biomarker outcomesand predictive value of the baseline PAM50 basedintrinsic subtype-ACOSOG Z1031[J].J Clin Oncol,2011,29(17):2342-2349.
[8] BERESFORD M,TUMUR I,CHAKRABARTI J,et al.A qualitative systematic review of the evidence base for non -cross -resistance be -tween steroidal and nonsteroidal aromatase inhibitors in metastatic breast cancer[J].Clinical Oncol,2011,23(3):209-215.
[9] FRASSOLDATI A,GUARNERI V,PIACENTINI F,et al.Letrozole versus letrozole plus Lapatinib (GW572016) in hormone-sensitive, HER2-negative operable breast cancer: adouble -blind, randomized, phase II studywith biomarker evaluation (EGF109077-LAP107692/LETLOB)[J]. Clin Breast Cancer,2008,8(1):97-100.
[10] SEMIGLAZOV VF,SEMIGLAZOV VV,DASHYAN GA,et al.Phase 2 randomized trial of primary endocrine therapy versus chemotherapy inpostmenopausal patients with estrogen receptorpositive breast cancer [J].Cancer,2007,110(2):244-254.
[11] DEL MASTRO L,CLAVAREZZA M,VENTURINI M.Reducing the risk of distant metastases in breast cancer patients: role of aromatase inhibitors[J].Cancer Treat Rev,2007,33(8):681-687.
[12] 甄世慧.乳腺癌新辅助内分泌治疗研究进展[J].现代实用医学,2015,10(27):1392-1394.
[13] 崔海东,刘坚.乳腺癌新辅助内分泌治疗进展[J].医学前沿,2014,43(12):14-17.